GULF PHARMACEUTICAL INDUSTRIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.941 AED | -0.11% |
|
-1.98% | +22.37% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,536 | 2,126 | 1,340 | 888.4 | 1,087 | - |
| Enterprise Value (EV) 1 | 1,536 | 2,126 | 2,133 | 888.4 | 1,867 | 1,087 |
| P/E ratio | -4.8 x | 32.9 x | -46.4 x | - | - | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 0.83 x | 0.54 x | 0.64 x | 0.6 x |
| EV / Revenue | - | - | 1.32 x | 0.54 x | 1.1 x | 0.6 x |
| EV / EBITDA | - | - | 14.8 x | 7.99 x | 80.1 x | - |
| EV / FCF | - | - | -48.1 x | 12.7 x | 24.5 x | - |
| FCF Yield | - | - | -2.08% | 7.89% | 4.08% | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,155,228 | 1,155,228 | 1,155,228 | 1,155,228 | 1,155,228 | - |
| Reference price 2 | 1.330 | 1.840 | 1.160 | 0.7690 | 0.9420 | 0.9420 |
| Announcement Date | 3/18/21 | 3/18/22 | 3/20/23 | 2/13/24 | - | - |
1AED in Million2AED
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1,616 | 1,638 | 1,694 | 1,798 |
| EBITDA 1 | - | - | 144.6 | 111.2 | 23.3 | - |
| EBIT 1 | - | - | 12.6 | -30.7 | -13.3 | - |
| Operating Margin | - | - | 0.78% | -1.87% | -0.79% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income | -293.2 | 64.4 | -29.4 | - | - | - |
| Net margin | - | - | -1.82% | - | - | - |
| EPS | -0.2770 | 0.0560 | -0.0250 | - | - | - |
| Free Cash Flow 1 | - | - | -44.4 | 70.1 | 76.1 | - |
| FCF margin | - | - | -2.75% | 4.28% | 4.49% | - |
| FCF Conversion (EBITDA) | - | - | - | 63.04% | 326.61% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/18/21 | 3/18/22 | 3/20/23 | 2/13/24 | - | - |
1AED in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 793 | - | 780 | - |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | 5.487 x | - | 33.48 x | - |
| Free Cash Flow 1 | - | - | -44.4 | 70.1 | 76.1 | - |
| ROE (net income / shareholders' equity) | - | - | -3.14% | - | -8.3% | -1.02% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 63.7 | 22.1 | 30.5 | - |
| Capex / Sales | - | - | 3.94% | 1.35% | 1.8% | - |
| Announcement Date | 3/18/21 | 3/18/22 | 3/20/23 | 2/13/24 | - | - |
1AED in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.942
AED
Average target price
0.72
AED
Spread / Average Target
-23.57%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +22.37% | 296M | |
| +4.09% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +20.72% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- JULPHAR Stock
- Financials Gulf Pharmaceutical Industries
